CCO - Highlights From EASL 2012 -Capsule Summaries

EASL Coverage @ CCO

2012 Annual Meeting of the European Association for the Study of the Liver*

April 18-22, 2012 | Barcelona, Spain

*CCO is an independent medical education company

that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

*Free registration required to view capsule summaries
Click here to register


ATOMIC: GS-7977 Plus PegIFN/RBV for 12 or 24 Weeks of Therapy Achieves Rapid, Sustained Viral Suppression in Treatment-Naive Patients With Genotype 1 HCV

ASPIRE: TMC435 Plus PegIFN/RBV Significantly Improves SVR24 Rates Over PegIFN/RBV Alone in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV Therapy

In Interim Analysis of Early Access Cohort, Telaprevir- and Boceprevir-Based Regimens Associated With Poor Safety but High On-Treatment Efficacy in Treatment-Experienced Genotype 1 Patients With Compensated Cirrhosis

EMERGE: PegIFN lambda-1a Associated With Comparable SVR Rates, Less Dose Modification vs PegIFN alfa-2a in Treatment-Naive Patients With Genotype 2/3 HCV

PROVIDE Interim Results: Substantial Proportion of Genotype 1 HCV Previous PegIFN/RBV Null Responders Achieved SVR Upon Retreatment With Boceprevir Plus PegIFN/RBV

Quadruple Therapy With Tegobuvir and GS-9256 Plus PegIFN/RBV Shows Potent Viral Suppression With Shortened Therapy in Genotype 1 HCV, but Safety Concerns Preclude Further Development of the Combination

Pilot Study: Interferon-Free Regimen of ABT-450/Ritonavir, ABT-072, ABT-450, and Ribavirin Achieved SVR12 in 91% of Noncirrhotic Treatment-Naive Genotype 1 HCV Patients With IL28B CC Genotype

Dual Oral Therapy With Daclatasvir and Asunaprevir Achieves 77% SVR in Genotype 1b HCV–Infected Patients With Previous Null Response, Medical Ineligibility, or Intolerance to Peginterferon/Ribavirin

Boceprevir or Telaprevir in Combination With PegIFN/RBV Improved On-Treatment Virologic Response Rates in Patients With Severe Genotype 1 Hepatitis C Recurrence Following Liver Transplantation vs Historical Treatment With PegIFN/RBV

Boceprevir Plus PegIFN/RBV Appears Safe, Effective in Genotype 1 HCV Therapy-Naive, HIV-Coinfected Patients on Stable Antiretroviral Therapy

Retrospective Analysis of Viral Kinetics During Treatment With Telaprevir Plus PegIFN/RBV Underscores Validity of Futility Rules

Miravirsen Safe, Well Tolerated With Durable Antiviral Activity in Phase IIa Trial in Treatment-Naive Patients With Chronic Genotype 1 HCV 

SOUND-C2 Interim Results: High Efficacy, Good Safety Profile of IFN-Free BI 201335, BI 207127, and RBV Combination Therapy in Treatment-Naive Patients With Genotype 1 HCV

BRISK-PS: Brivanib Fails to Improve OS in Patients With Advanced HCC Who Failed Sorafenib

Co-Pilot Study: IFN-Free Regimen of ABT-450/Ritonavir, ABT-333, and Ribavirin Achieved 12-Week SVR Rates > 90% in Genotype 1 HCV

VITAL-1: Interim Results Indicate Alisporivir Plus Ribavirin Achieved High SVR Rates With or Without Addition of PegIFN in Treatment-Naive Patients With Genotype 2/3 HCV Infection

INFORM-SVR: Safety and Efficacy of Interferon-Free Combination of Mericitabine, Ritonavir-Boosted Danoprevir, and Ribavirin in Treatment-Naive Patients With Genotype 1b HCV

SVR Rates Similar in Boceprevir-Treated Patients Randomized to RBV Dose Reduction or Erythropoietin for Anemia Management in Prospective Trial

High SVR Rates and Acceptable Safety Profile With Interferon-Free, All-Oral, Quad Regimen of GS-5885, GS-9451, Tegobuvir, and Ribavirin in Treatment-Naive Patients With Genotype 1 HCV Infection

Interferon-Free Combination of Daclatasvir (NS5A Inhibitor) Plus GS-7977 (NS5B Inhibitor) Demonstrates High Rates of SVR4 in Treatment-Naive Patients With Chronic Genotype 1, 2, or 3 HCV Infection

CCO Slideset

Highlights From EASL 2012 (coming soon)